ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms of Thromboinflammation

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 1428

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory Medicine and Pathology Department, Group of Molecular Pathology and Pharmacogenetics, Biomedical Research Institute from Murcia (IMIB), Santa Lucía General University Hospital, 30202 Cartagena, Spain
Interests: cancer-associated thrombosis; thromboinflammation; biomarkers; molecular pathology; personalized medicine; oncology; hematology; immune system

Special Issue Information

Dear Colleagues,

Thromboinflammation—an intricate interplay between the coagulation cascade and immune response—is a key driver in the pathophysiology of numerous diseases. This Special Issue will explore the molecular and cellular mechanisms behind thromboinflammation across a broad spectrum of clinical contexts, including sepsis, ischemic stroke, autoimmune and inflammatory diseases, organ transplant rejection, and malignancies such as solid tumors and hematological disorders.

We welcome original research and comprehensive reviews investigating the immune–coagulation interface, signaling pathways promoting thromboinflammatory responses, platelet–leukocyte interactions, endothelial dysfunction, and the role of neutrophil extracellular traps (NETs). Studies identifying novel biomarkers or proposing translational approaches to target thromboinflammatory pathways are especially encouraged.

By encompassing both common and context-specific mechanisms, this Special Issue will advance our understanding of thromboinflammation and support the development of targeted therapeutic strategies across diverse disease settings.

Dr. Ana B. Arroyo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thromboinflammation
  • coagulation
  • inflammation
  • immune system
  • sepsis
  • stroke
  • autoimmune diseases
  • cancer
  • hematology
  • biomarkers
  • translational medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 3002 KB  
Review
Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors
by Alice Ilari, Maria Ida Abbate, Melina Verso, Mara Graziani, Pietro Cafaro, Luca Sala, Francesca Colonese, Diego Luigi Cortinovis and Stefania Canova
Int. J. Mol. Sci. 2026, 27(4), 1874; https://doi.org/10.3390/ijms27041874 - 15 Feb 2026
Viewed by 808
Abstract
The incidence of cancer-associated thrombosis has increased in recent years. While the association between venous thromboembolism (VTE) and chemotherapy is well established, there is no clear link between immune checkpoint inhibitors (ICIs) and VTE risk. Many risk assessment models (RAMs) have been developed [...] Read more.
The incidence of cancer-associated thrombosis has increased in recent years. While the association between venous thromboembolism (VTE) and chemotherapy is well established, there is no clear link between immune checkpoint inhibitors (ICIs) and VTE risk. Many risk assessment models (RAMs) have been developed to identify high-risk patients who need prophylaxis. However, these models are validated in patients undergoing chemotherapy, while they are scarce in those receiving immunotherapy. Moreover, the mechanisms linking ICIs to thrombosis are still a matter of debate. They include the upregulation of pro-inflammatory intracellular pathways, the release of cytokines, the activation of innate immune cells, the release of tissue factors and platelet activation, and the increase in adhesion molecules, thus resulting in the recruitment of agents involved in coagulation. Promising biomarkers are emerging to identify patients undergoing ICIs who are at high risk of developing VTE and need prophylaxis. In this review we investigate the possible causation between cancer-associated thrombosis (CAT) and immunotherapy and the underlying pathophysiological mechanisms. Thus, we suggest the most appropriate therapeutic approaches based on currently available data. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Thromboinflammation)
Show Figures

Graphical abstract

Back to TopTop